These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18463226)

  • 1. Immunological evidence for functional rather than structural mimicry by a Shigella flexneri Y polysaccharide-mimetic peptide.
    Borrelli S; Hossany RB; Pinto BM
    Clin Vaccine Immunol; 2008 Jul; 15(7):1106-14. PubMed ID: 18463226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics.
    Phalipon A; Folgori A; Arondel J; Sgaramella G; Fortugno P; Cortese R; Sansonetti PJ; Felici F
    Eur J Immunol; 1997 Oct; 27(10):2620-5. PubMed ID: 9368618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and immunochemical characterization of a chimeric glycopeptide corresponding to the Shigella flexneri Y O-polysaccharide and its peptide mimic MDWNMHAA.
    Hossany BR; Johnston BD; Wen X; Borrelli S; Yuan Y; Johnson MA; Pinto BM
    Carbohydr Res; 2009 Aug; 344(12):1412-27. PubMed ID: 19467535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.
    Chu CY; Liu BK; Watson D; Szu SS; Bryla D; Shiloach J; Schneerson R; Robbins JB
    Infect Immun; 1991 Dec; 59(12):4450-8. PubMed ID: 1937803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid.
    Polotsky VY; Robbins JB; Bryla D; Schneerson R
    Infect Immun; 1994 Jan; 62(1):210-4. PubMed ID: 8262629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
    Taylor DN; Trofa AC; Sadoff J; Chu C; Bryla D; Shiloach J; Cohen D; Ashkenazi S; Lerman Y; Egan W
    Infect Immun; 1993 Sep; 61(9):3678-87. PubMed ID: 8359890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural mimicry of O-antigen by a peptide revealed in a complex with an antibody raised against Shigella flexneri serotype 2a.
    Theillet FX; Saul FA; Vulliez-Le Normand B; Hoos S; Felici F; Weintraub A; Mulard LA; Phalipon A; Delepierre M; Bentley GA
    J Mol Biol; 2009 May; 388(4):839-50. PubMed ID: 19328810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies specific for O-antigenic polysaccharides of Shigella flexneri: clones binding to II, II:3,4, and 7,8 epitopes.
    Carlin NI; Lindberg AA
    J Clin Microbiol; 1983 Nov; 18(5):1183-9. PubMed ID: 6196376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.
    Zhang T; Yu W; Wang Y; Hu T
    Vaccine; 2015 Jun; 33(28):3208-14. PubMed ID: 25964170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WaterLOGSY NMR experiments in conjunction with molecular-dynamics simulations identify immobilized water molecules that bridge peptide mimic MDWNMHAA to anticarbohydrate antibody SYA/J6.
    Szczepina MG; Bleile DW; Müllegger J; Lewis AR; Pinto BM
    Chemistry; 2011 Oct; 17(41):11438-45. PubMed ID: 21887835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a.
    Clément MJ; Fortuné A; Phalipon A; Marcel-Peyre V; Simenel C; Imberty A; Delepierre M; Mulard LA
    J Biol Chem; 2006 Jan; 281(4):2317-32. PubMed ID: 16251186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH; Freier S; Shor R; Farzam N; Block C; Lison M; Shiff E; Ashkenazi S
    Pediatr Infect Dis J; 1995 Oct; 14(10):859-65. PubMed ID: 8584312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice.
    Lesinski GB; Smithson SL; Srivastava N; Chen D; Widera G; Westerink MA
    Vaccine; 2001 Feb; 19(13-14):1717-26. PubMed ID: 11166896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
    J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saturation-transfer difference NMR studies for the epitope mapping of a carbohydrate-mimetic peptide recognized by an anti-carbohydrate antibody.
    Johnson MA; Pinto BM
    Bioorg Med Chem; 2004 Jan; 12(1):295-300. PubMed ID: 14697795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies specific for Shigella flexneri lipopolysaccharides: clones binding to type I and type III:6,7,8 antigens, group 6 antigen, and a core epitope.
    Carlin NI; Lindberg AA
    Infect Immun; 1986 Jul; 53(1):103-9. PubMed ID: 2424839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.
    Phalipon A; Costachel C; Grandjean C; Thuizat A; Guerreiro C; Tanguy M; Nato F; Vulliez-Le Normand B; Bélot F; Wright K; Marcel-Peyre V; Sansonetti PJ; Mulard LA
    J Immunol; 2006 Feb; 176(3):1686-94. PubMed ID: 16424198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of five Shigella flexneri variant Y-specific monoclonal antibodies using defined saccharides and glycoconjugate antigens.
    Carlin NI; Bundle DR; Lindberg AA
    J Immunol; 1987 Jun; 138(12):4419-27. PubMed ID: 2438343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies against the surface antigens of Shigella flexneri serotype 1b and Shigella dysenteriae serotype 1.
    Suzuki K; Takeda T
    Microbiol Immunol; 1989; 33(11):897-906. PubMed ID: 2687648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.